BoA Boosts The Price Target for Nvidia

Earn While You Learn! ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ [EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!]( Hello investor, BoA Boosts The Price Target for Nvidia So far, the earnings season has been a mixed bag. Out of 70% S&P 500 companies that reported earnings, 75% of them have beaten expectations. Not too bad. There were big winners and losers. Wall Street rewarded or punished them accordingly. Investors aren’t biased toward one direction at this moment. Bank of America remains extremely bullish on Nvidia. Its analyst Vivek Arya boosted his price target which represented a whopping 38% upside from Nvidia’s current stock price. The stock already rallied more than 176% this year alone. Why? He pointed to Taiwan Semiconductor’s strong third-quarter results as evidence that Nvidia is going to have another phenomenal quarter. Don’t forget that CEO Jensen Huang said demand for its Blackwell chip is “insane.” Bank of America analyst Vivek Arya (Photo: CNBC) Moreover, Bloomberg said sales of Apple’s new iPhone 16 in China increased 20% in their first weeks versus the iPhone 15. So, Apple is off to a good start for its iPhone release that could trigger a supercycle, especially with its AI features. And of course, Netflix reported a strong quarter. But there were some concerns. Housing starts and building permits fell in September, according to a Census Bureau report. There are some areas in the economy that struggle in a high interest rate environment. The success had been limited to certain areas, like the AI frenzy. Even Big Tech companies are projected to see their revenue growth rate slow. Regardless, Wall Street remains bullish on stocks. Rob Williams at Sage Advisory believes stocks could rally through November. Typically, stocks tend to underperform before the election but it looks like it could be a “buy the rumor, sell the news” type of a move. - “Usually it’s the other way around — the market’s hesitant, and then it does well after the election. Now we’re getting the reverse of it and ... Maybe you get the opposite of what we had — stocks will be strong into the election and then have some volatility fall on the election,” he said. Big Tech’s earnings reports will be critical to see if stocks can justify their lofty valuations. It might be the biggest catalyst before the presidential election, so volatility is unlikely to go away anytime soon. Looking for a Good Medical Device Stock? This One Is Scaling Fast With A Drug-Free Opioid Alternative Today’s Pick: Zynex, Inc. (ZYXI) Recently, some scholars have debated about whether Albert Einstein actually said that compounding interest is the eighth wonder of the universe. No matter. Any time you can find a stock for your portfolio that’s compounding nicely, it’s a good candidate for your portfolio. This is a phenomenal grower: (Source: Zynex) Besides one bad quarter, Zynex never failed to grow year-to-year quarter under 11% per quarter since 2017. What exactly does Zynex do? They focus on electrotherapy through three primary lines of business. First, electrotherapy for strokes, spinal cord injuries, and traumatic brain injuries. Second, electrotherapy for digestive issues. (Source: Zynex) Third, their NexWave pain management system might be their biggest opportunity. The company is marketing the product as an alternative to opioids for pain management. The timing is perfect. Pharmaceutical companies are quietly working towards a multi-billion dollar settlement for their opioid business practices. Even better, their treatments lend themselves to recurring revenue. It’s not just a one-time device sale. And these are widely profitable. Zynex has earned gross margins north of 79% in the past five years. (Source: Zynex) Best of all: Their NexWave competition all went out of business. In 2016, the inspector general audited Zynex and both of their competitors. Zynex passed. The other electrotherapy pain management companies didn’t -- they shut down after millions of dollars in fines. CEO Thomas Sandgaard’s reaction? - “We literally have no competition left.” Zynex checks a lot of boxes financially. Here are just a few of the highlights: - Insiders still hold a remarkable 51% of shares. We love it when we see this. Leadership has a financial incentive to increase shareholder value. Then their gains become your gains. - Their market cap is still just $254 million. Lots more capital could flow in as long as they continue to grow. - They boast a current ratio of 4.06. Cash on the balance sheet lets them invest in new opportunities as they arise. Bottom Line: This is one of the most exciting growth stocks that investors are overlooking. If you want a bet on smaller-cap companies, this stock is the one to look at.   [EARN WHILE YOU LEARN! JOIN OUR FREE LIVE TRADING SESSION!](     © All Rights Reserved, Trade Alliance [Unsubscribe]( | [Manage Preferences](